Product Images Varenicline Tartrate
View Photos of Packaging, Labels & Appearance
- Chemical Structure - 89b8956b cf71 4791 8e55 598ff52656f3 01
- figure1 - 89b8956b cf71 4791 8e55 598ff52656f3 02
- logo - 89b8956b cf71 4791 8e55 598ff52656f3 03
- dis - 89b8956b cf71 4791 8e55 598ff52656f3 04
- Starter carton pack - 89b8956b cf71 4791 8e55 598ff52656f3 05
- starter wallet pack - 89b8956b cf71 4791 8e55 598ff52656f3 06
- 0.5 mg 56 bottles - 89b8956b cf71 4791 8e55 598ff52656f3 07
- 1 mg- 56 bottles pack - 89b8956b cf71 4791 8e55 598ff52656f3 08
- Continuing wallet pack - 89b8956b cf71 4791 8e55 598ff52656f3 09
- Continuing carton pack - 89b8956b cf71 4791 8e55 598ff52656f3 10
- Image - 89b8956b cf71 4791 8e55 598ff52656f3 188 1
- Image - 89b8956b cf71 4791 8e55 598ff52656f3 192 1
Product Label Images
The following 12 images provide visual information about the product associated with Varenicline Tartrate NDC 68462-894 by Glenmark Pharmaceuticals Inc., Usa, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Chemical Structure - 89b8956b cf71 4791 8e55 598ff52656f3 01
figure1 - 89b8956b cf71 4791 8e55 598ff52656f3 02
logo - 89b8956b cf71 4791 8e55 598ff52656f3 03
Distributed by Glenmark.*
dis - 89b8956b cf71 4791 8e55 598ff52656f3 04
Starter carton pack - 89b8956b cf71 4791 8e55 598ff52656f3 05
starter wallet pack - 89b8956b cf71 4791 8e55 598ff52656f3 06
0.5 mg 56 bottles - 89b8956b cf71 4791 8e55 598ff52656f3 07
1 mg- 56 bottles pack - 89b8956b cf71 4791 8e55 598ff52656f3 08
Continuing wallet pack - 89b8956b cf71 4791 8e55 598ff52656f3 09
Continuing carton pack - 89b8956b cf71 4791 8e55 598ff52656f3 10
Not available.*
Image - 89b8956b cf71 4791 8e55 598ff52656f3 188 1
Image - 89b8956b cf71 4791 8e55 598ff52656f3 192 1
Figure 3 shows the continuous abstinence rate during the nontreatment follow-up period. The graph displays the abstinence rates for Vararicine wbiets and Placebo, with different dosage levels. The x-axis represents the weeks of nontreatment follow-up, while the y-axis shows the continuous abstinence rate. The graph also includes numerical values for each week of follow-up. Unfortunately, the rest of the text is not readable.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
